Many Boston Scientific Corporation (NYSE:BSX) insiders ditched their stock over the past year, which may be of interest to the company's shareholders. When evaluating insider transactions, knowing ...

Boston Scientific continues to deliver robust growth, but valuation limits upside despite strong execution and leading positions in key medical device markets. BSX's growth drivers—Farapulse (PFA), ...

Boston Scientific Corporation (NYSE:BSX) is one of the best healthcare AI stocks to buy now. On December 12, TD Cowen reaffirmed a Buy rating on Boston Scientific Corporation (NYSE:BSX) and kept a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Boston Scientific has been ...

Boston Scientific is one of those companies that most people never think about until they need it. Its products are not seen on drugstore shelves or marketed on television. Instead, they sit inside ...

Boston Scientific bought its newly opened 400,000 sq. ft. Maple Grove facility from Ryan Cos. for $188.8 million. The office pricing sits at $472 per square foot, among the highest in years The site ...

Boston Scientific is proving itself to be a pivotal force in the pulsed-field ablation space. The Marlborough, MA-based company continues to be at the forefront of PFA with its technology The firm ...

Boston Scientific (BSX) has disclosed a new risk, in the Regulation category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights ...

Boston Scientific’s third-quarter revenue topped $5 billion, up 20.3% year over year. Growth eased slightly from the second quarter, when sales rose more than 22%. Urology led the gains, up 28% year ...